공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

측면유동검사(LFA) 시장 : 성장, 동향, 예측(2020-2025년)

Lateral Flow Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 927998
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


측면유동검사(LFA) 시장 : 성장, 동향, 예측(2020-2025년) Lateral Flow Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 측면유동검사(LFA) 시장은 예측기간 동안 거의 3.9%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 주요 시장 성장요인은 감염, HIV, 암의 세계적 만연이며, 높아지는 사망률을 근절하기 위한 효율적인 치료에서의 새로운 진단 방법이 필요합니다.

세계의 측면유동검사(LFA: Lateral Flow Assay) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 용도별·기술별·제품별·이용자별·지역별 시장 규모 추이 및 예측, 경쟁 상황, 주요 기업 개요, 시장 기회 등의 종합적인 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 기술 진보와 함께 POC 검사 수요 증가
    • 세계적인 감염 발생률과 함께 가정용 기기 채용 증가
  • 시장 성장 억제요인
  • Porter's Five Force 분석

제5장 시장 세분화

  • 용도별
    • 임상검사
    • 의약품 개발 및 품질 검사
    • 기타
  • 기술별
    • Sandwich Assay
    • Competitive Assay
    • Multiplex Assay
  • 제품별
    • Lateral Flow Reader
    • 키트 및 시약
  • 이용자별
    • 홈케어
    • 병원/클리닉
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • PerkinElmer Inc
    • Merck KGaA
    • QIAGEN NV
    • Abbott Laboratories(Alere Inc)
    • Quidel Corporation
    • Hologic Inc
    • Thermo Fisher Scientific Inc
    • bioMerieux SA
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc

제7장 시장 기회 및 향후 동향

LSH 20.06.05

The lateral flow assay market is projected to register a CAGR of 6.3% over the forecast period, with a revenue of USD 7,533 million in 2020 and expected to reach USD 11,551 million by 2026.

The COVID-19 pandemic has a positive impact on the market. Instead of sending patient samples to the laboratory, the usage of lateral flow test kits can be convenient as they are smaller, portable, and can be controlled with minimal training. This makes them attractive for deployment outside of healthcare facilities, in low- and middle-income countries, or for those countries rolling out mass population screening programs. Even though they are less accurate than PCR tests, their low cost, speed, and ease of use make lateral flow tests particularly attractive to countries that do not have extensive laboratory facilities or trained health workers to easily conduct PCR tests for COVID-19 screening. Some countries, such as Slovakia and the United Kingdom are extensively using lateral flow tests as a means of mass screening programs. For example, the British government has been monitoring the use of the Innova SARS-CoV-2 Antigen Rapid Qualitative Test in Liverpool, which currently has high COVID-19 rates, and plans to roll it out nationwide.

A major factor contributing to market growth is the growing global rate of infectious diseases, HIV, cancer, which requires new diagnostic methods of effective treatment to end the growing mortality rate. For example, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), in 2019, 24.5 million people living with HIV are receiving antiretroviral treatment worldwide.

The technical advancements in the field of lateral flow assays (LFA) have also boosted the market growth. In recent years, major advances in LFA development have included novel signal enhancement techniques, the use of new labels, improved quantification systems and simultaneous detection. Some new techniques have been used to enhance the signal from gold nanoparticles (colloidal nanoparticles) GNPs have adopted silver enhancement technology or combinations of GNPs with an enzyme (such as horseradish peroxidase), which results in catalytic amplification of the signal.

Additionally, increased participation of the government to control the outbreaks of infectious diseases and the increasing awareness programs to enhance the spread of infections, diagnosis, and prevention, along with the launch of diagnosis systems at home care settings, are expected to contribute to the growth of the global market during the forecast period.

Key Market Trends

Clinical Testing, by Application is Expected to Hold the Largest Market Share in the Lateral Flow Assay Market

The pandemic has drastically increased launches and research in the field of clinical testing, bolstering the segment growth. Roche in September 2020, launched a SARS-CoV-2 Rapid Antigen Test for markets accepting the CE Mark. The SARS-CoV-2 Rapid Antigen Test is for use in point-of-care settings for both symptomatic and asymptomatic people. In October 2020, Access Bio launched Lateral Flow COVID-19 Antigen Test, the US FDA approved the product to detect SARS-CoV-2 infections.

The clinical testing segment is anticipated to hold the largest market share in the LFA market due to its importance in identifying the detection of the disease with a rise in the incidence of infectious diseases. According to the World Health Organization, Global Tuberculosis Report 2020, approximately 1.4 million people died from Tuberculosis-related illnesses in 2019 and nearly 10 million individuals developed tuberculosis in 2019. Hence, the growing burden of tuberculosis is expected to drive the need for rapid and affordable diagnostics, especially in developing countries, which aids in the growth of the studied market.

The increased demand for the segment is owing to an increase in the new approvals of self-test devices, such as Atomo HIV Self-Test, TRUSTline HIV-Ab/Ag 4th Gen Rapid Test, Dr Trust Hiv Sure, and others, developed in the recent years. These self-test devices and kits help the patients in assurance, earlier diagnosis, enhanced convenience, and ease of use, which are likely to fuel the market.

North America Dominates the Market and it is Expected to do the Same in the Forecast Period

North America is expected to dominate the overall LFA market throughout the forecast period owing to a rise in the incidence of various infectious diseases such as Lyme disease, tuberculosis, and an increased mortality rate associated with HIV/AIDS in the region. In North America, the United States holds the largest market share due to increased patient pool and high affordability with increasing disposable income.

The pandemic hit the region very hard and forced the government to mass screening programs boosting the market growth in the region. In 2020, Abbott Laboratories ramped up its production of coronavirus test kits, including a new tool that could enable mass COVID-19 screening. The company has thus announced that it's developing the fourth diagnostic test for the coronavirus: A "lateral flow" blood test that could provide mass testing to the general population

As per the US Department of Health & Human Services report published in January 2020, about 37,832 people in the United States were diagnosed with HIV in 2018, and 38,000 new HIV infections still occur in the United States. It has also been reported that there is a rapid spread of various infectious diseases such as meningitis, urinary tract infections necessitating the immediate diagnosis demanding the fast diagnostic test devices fueling the market. Furthermore, the increased adoption rate of advanced infrastructure, the volume of diagnostic centers, rise in awareness among the people are factors estimated to boost the market in the region, contributing to its outstanding share of the global market revenue during the forecast period.

Competitive Landscape

The LFA market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies, such as mergers and acquisitions, while others are developing new test methods for the diagnosis and introducing new products to retain their market share. For instance, in February 2019, Abbott announced the availability of its latest rapid influenza diagnostic test (RIDT), BinaxNOW Influenza A & B Card 2, which was granted under the Clinical Laboratory Improvements Amendments (CLIA) by the US Food and Drug Administration (FDA) for rapid detection of influenza virus, which is expected to have a positive impact on the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Hologic Inc., Quidel Corporation, PerkinElmer Inc., and bioMerieux SA.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Demand for Point-of-care Testing with Technological Advancements
    • 4.2.2 Rise in Adoption of Home-based Devices, along with Global Incidence of Infectious Diseases
  • 4.3 Market Restraints
    • 4.3.1 Stringent and Tedious Regulatory Framework that Delays the Approval of Products
    • 4.3.2 Risk of False Results and Reluctance Toward these Products among the People in Emerging Nations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Clinical Testing
      • 5.1.1.1 Pregnancy Testing
      • 5.1.1.2 Influenza Testing
      • 5.1.1.3 Tuberculosis
      • 5.1.1.4 D-Dimer Testing
      • 5.1.1.5 Other Clinical Testings
    • 5.1.2 Drug Abuse Testing
    • 5.1.3 Other Applications
  • 5.2 By Technique
    • 5.2.1 Sandwich Assay
    • 5.2.2 Competitive Assay
    • 5.2.3 Multiplex Assay
  • 5.3 By Product
    • 5.3.1 Lateral Flow Readers
      • 5.3.1.1 Digital/Mobile Readers
      • 5.3.1.2 Benchtop Readers
    • 5.3.2 Kits and Reagents
  • 5.4 By End User
    • 5.4.1 Home Care
    • 5.4.2 Hospitals and Clinics
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 PerkinElmer Inc.
    • 6.1.2 Merck KGaA
    • 6.1.3 QIAGEN NV
    • 6.1.4 Abbott Laboratories (Alere Inc.)
    • 6.1.5 Quidel Corporation
    • 6.1.6 Hologic Inc.
    • 6.1.7 Thermo Fisher Scientific Inc.
    • 6.1.8 bioMerieux SA
    • 6.1.9 Becton, Dickinson and Company
    • 6.1.10 Bio-Rad Laboratories Inc.
    • 6.1.11 Abcam PLC
    • 6.1.12 Danaher Corporation
    • 6.1.13 F. Hoffmann-La Roche AG
    • 6.1.14 Siemens AG
    • 6.1.15 Chembio Diagnostic Systems, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q